Abstract The COVID-19 pandemic poses a challenge to certain standards in patent law as well pharmaceutical law. This paper discusses questions whether and under what conditions government-ordered or privately claimed compulsory licensing can contribute controlling the pandemic. existing obstacles conflicts current legal framework, such lack of international harmonization coherence between (comp...

Innovation is slowing greatly in the pharmaceutical sector. It is considered here how part of the problem is due to overly limiting intellectual property relations in the sector. On the other hand, computing and software in particular are characterized by great richness of intellectual property frameworks. Could the intellectual property ecosystem of computing come to the aid of the biosciences...

In this work the electrooxidation half-wave potentials of some Benzoxazines were predicted from their structural molecular descriptors by using quantitative structure-property relationship (QSAR) approaches. The dataset consist the half-wave potential of 40 benzoxazine derivatives which were obtained by DC-polarography. Descriptors which were selected by stepwise multiple selection procedure ar...

From the dawn of time, the sharing of knowledge has been one of the main forces driving science and innovation. Yet in recent decades, a proprietary culture, which wrongly posits that all intellectual property must be restricted, has spread across the pharmaceutical industry and threatens to stall the engine that has given us so many valuable treatments. This paper argues that pharmaceutical co...

Patent protection and factors unique to prescription drugs weaken the forces keeping prices near costs for other products. A growing public consensus that affordable drugs should be available to all is likely to increase the upward pressure on prices. To restore competition to all parts of the pharmaceutical industry, we propose a new institute at the National Institutes of Health that would co...

This paper examines the rationale for intellectual property protection in the development of new pharmaceutical products. Prior survey studies of R&D executives have found that patents play a more critical role in appropriating the benefits of innovation in pharmaceuticals compared to other high tech industries. This paper considers why this is so based on an analysis of the economic characteri...

pharmaceutical industry is currently undergoing a transient phase with new orientation. loss of financial resources, presence of new therapeutic agents and increasing cost of research and development have called for a full.scale restructuring within the pharmaceutical industry to retain even the most basic competitiveness. the development of new technologies has been as one way out of the dilem...